Nanomedicine Market by Molecule Type (Nanodevices, Nanoparticles, Nanoshells), Modality (Diagnostics, Treatment), Application, Indication - Global Forecast 2024-2030

Nanomedicine Market by Molecule Type (Nanodevices, Nanoparticles, Nanoshells), Modality (Diagnostics, Treatment), Application, Indication - Global Forecast 2024-2030


The Nanomedicine Market size was estimated at USD 206.25 billion in 2023 and expected to reach USD 227.37 billion in 2024, at a CAGR 10.91% to reach USD 425.88 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Nanomedicine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Nanomedicine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Nanomedicine Market, highlighting leading vendors and their innovative profiles. These include AMAG Pharmaceuticals, Inc., Amgen Inc., Arrowhead Pharmaceuticals, Inc., Bausch Health Companies Inc., Bayer Healthcare, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eisai Co Ltd, F. Hoffmann-La Roche AG, Galen Ltd, General Electric Company, Gilead Sciences, Inc., Ipsen SA, Jazz Pharmaceuticals plc, Lantheus Holdings, Inc., Leadient BioSciences Inc., Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Nano spectra Biosciences, Inc., Novo Nordisk A/S, OSARTIS GmbH, Pacira BioSciences Inc., Pfizer Inc., Sanofi S.A., Taiwan Liposome Company, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Ltd., UCB SA, and Zimmer Biomet Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Nanomedicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

Molecule Type

Nanodevices

Nanoparticles
Dendrimers
Hydrogel Nanoparticles
Inorganic Nanoparticles
Liposomes
Metal & Metal Oxide Nanoparticles
Polymers & Polymer Drug Conjugates

Nanoshells

Nanotubes
Modality

Diagnostics

Treatment
Application

Diagnostic Imaging

Drug Delivery

Implants

Regenerative Medicine

Vaccines
Indication

Clinical Cardiology

Clinical Oncology

Immunology

Infectious Diseases

Neurology

Ophthalmology

Orthopedics

Urology
Region

Americas
Argentina
Brazil
Canada
Mexico
United States

California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Nanomedicine Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Nanomedicine Market?
3. What are the technology trends and regulatory frameworks in the Nanomedicine Market?
4. What is the market share of the leading vendors in the Nanomedicine Market?
5. Which modes and strategic moves are suitable for entering the Nanomedicine Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Nanomedicine Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of chronic diseases and need for efficient treatment
5.1.1.2. Utilization of nanomedicine technology for personalized medicine
5.1.1.3. Applications in vitro diagnostics and in vivo imaging
5.1.2. Restraints
5.1.2.1. High cost of development and commercialization of nanomedicine
5.1.3. Opportunities
5.1.3.1. Strategic alliances for development of novel nanomedicine
5.1.3.2. Favorable funding landscape for research and development of nanomedicine
5.1.4. Challenges
5.1.4.1. Limited availability of clinical evidence
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Nanomedicine Market, by Molecule Type
6.1. Introduction
6.2. Nanodevices
6.3. Nanoparticles
6.4.1. Dendrimers
6.4.2. Hydrogel Nanoparticles
6.4.3. Inorganic Nanoparticles
6.4.4. Liposomes
6.4.5. Metal & Metal Oxide Nanoparticles
6.4.6. Polymers & Polymer Drug Conjugates
6.4. Nanoshells
6.5. Nanotubes
7. Nanomedicine Market, by Modality
7.1. Introduction
7.2. Diagnostics
7.3. Treatment
8. Nanomedicine Market, by Application
8.1. Introduction
8.2. Diagnostic Imaging
8.3. Drug Delivery
8.4. Implants
8.5. Regenerative Medicine
8.6. Vaccines
9. Nanomedicine Market, by Indication
9.1. Introduction
9.2. Clinical Cardiology
9.3. Clinical Oncology
9.4. Immunology
9.5. Infectious Diseases
9.6. Neurology
9.7. Ophthalmology
9.8. Orthopedics
9.9. Urology
10. Americas Nanomedicine Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Nanomedicine Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Nanomedicine Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. AMAG Pharmaceuticals, Inc.
14.1.2. Amgen Inc.
14.1.3. Arrowhead Pharmaceuticals, Inc.
14.1.4. Bausch Health Companies Inc.
14.1.5. Bayer Healthcare
14.1.6. Biogen Inc.
14.1.7. Bristol-Myers Squibb Company
14.1.8. Celgene Corporation
14.1.9. Eisai Co Ltd
14.1.10. F. Hoffmann-La Roche AG
14.1.11. Galen Ltd
14.1.12. General Electric Company
14.1.13. Gilead Sciences, Inc.
14.1.14. Ipsen SA
14.1.15. Jazz Pharmaceuticals plc
14.1.16. Lantheus Holdings, Inc.
14.1.17. Leadient BioSciences Inc.
14.1.18. Mallinckrodt Pharmaceuticals
14.1.19. Merck & Co., Inc.
14.1.20. Nano spectra Biosciences, Inc.
14.1.21. Novo Nordisk A/S
14.1.22. OSARTIS GmbH
14.1.23. Pacira BioSciences Inc.
14.1.24. Pfizer Inc.
14.1.25. Sanofi S.A.
14.1.26. Taiwan Liposome Company, Ltd.
14.1.27. Takeda Pharmaceutical Company Limited
14.1.28. Teva Pharmaceuticals Ltd.
14.1.29. UCB SA
14.1.30. Zimmer Biomet Holdings, Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. NANOMEDICINE MARKET RESEARCH PROCESS
FIGURE 2. NANOMEDICINE MARKET SIZE, 2023 VS 2030
FIGURE 3. NANOMEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. NANOMEDICINE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. NANOMEDICINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. NANOMEDICINE MARKET DYNAMICS
FIGURE 7. NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
FIGURE 8. NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. NANOMEDICINE MARKET SIZE, BY MODALITY, 2023 VS 2030 (%)
FIGURE 10. NANOMEDICINE MARKET SIZE, BY MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. NANOMEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 12. NANOMEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. NANOMEDICINE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 14. NANOMEDICINE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES NANOMEDICINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES NANOMEDICINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. NANOMEDICINE MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. NANOMEDICINE MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings